

Biographical sketch CIRO ISIDORO

Photo



Name CIRO ISIDORO

Email ciro.isidoro@med.uniupo.it

Appointed Associate Professor of General Pathology

Qualified Full Professor of Clinical Biochemistry and Clinical Molecular Biology

Qualified Full Professor of Medical Oncology

Qualified Full Professor of General Pathology and Clinical Pathology

Affiliation Università del Piemonte Orientale, Department of Health Sciences; via Paolo Solaroli 17 – 28100, Novara (Italy)

Website: <http://www.isidorolab.com/>

Education:

1983 – Laurea *Summa cum Laude* - Doctor in Biological Sciences (D.Sc.), Università di Torino (Italy)

1984 – National License for Board of Doctor Biologists

1999 - Laurea *Summa cum Laude* - Doctor in Medicine and Surgery (M.D.), Università del Piemonte Orientale (Novara, Italy)

2000 – National License for Board of Medical Doctors and Surgeons.

Representative Careers and affiliations:

1986-1989 PhD fellow-Assistant Researcher at the Institut fuer Pathobiochemie, Westfaelish Wilhems Universitaet Muenster (Germany)

1989-1992 Post-doc-Assistant Researcher at Università di Torino, Dipartimento di Medicina e Oncologia Sperimentale (Italy)

1993-1999 Assistant Professor of General Pathology, University of Turin (Italy)

2000 to date: Associate Professor of Cell Pathology and of Experimental Oncology, School of Medicine, Università del Piemonte Orientale (Novara, Italy).

2000-2000: Visiting Professor at Institute fuer Physiologische Chemie (Prof. A. Hasilik), Klinikum der Philipps-Universitaet Marburg (D)

2002-2005: Visiting Professor at Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology, University of Bristol (UK).

2005 to date: overseas advisor of PhD students at Mahidol University, at Chulalongkorn University, Bangkok; at Khon Kaen University (Thailand)

2013 to date: Visiting Professor, Siriraj Faculty of Medicine, Mahidol University of Bangkok (Thailand).

2016 to date: Visiting Professor, Department of Cell Biology, Oklahoma University Health Scienc

e Center (OKC, US).

Representative Awards:

2014: Professor Honoris Causa Faculty of Medicine and Pharmacy, Université de la Franche-Comté of Besançon(France).

2015: member of the Scientific board of « Integrative Cancer Research Center of the Georgia Institute of Technology », Georgia Tech University, Georgia (Atlanta, US)

2015: Executive Vice-President of the International Association of Traditional and Complementary Medicine.

EDITORIAL BOARD

Co-Editor in Chief of J Traditional and Complementary Medicine

Associate Editor of Autophagy, Molecular Carcinogenesis, BMC Cancer, Genes and Cancer, J. Ovarian Research, J. Alzheimer's Disease, J. Molecular Signaling, Current Biomarkers, Frontiers in Endocrinology and Ageing, Am J Cancer Biol, (others)

Bibliometric index : Google Scholar H Index = 35; Citations = 8.214; Scopus H Index = 32

Scientific Publication list

PUBMED <https://www.ncbi.nlm.nih.gov/pubmed/?term=isidoro+c>

Google Scholar: <https://scholar.google.it/citations?user=X8le7K8AAAAJ&hl=it>

Research Areas:

Autophagy in Cancer and in Neurodegeneration. Epigenetic regulation of Autophagy and cell death. Anti-aging and anti-cancer Nutraceuticals. Complementary medicine. Organelle biogenesis, vesicular traffic and diseases. Nanotheranostics ('in cellulo' imaging).

Selected Publications (out of 140 in peer-reviewed journals):

1. Thongchot S, Ferraresi A, Vidoni C, Loilome W, Yongvanit P, Namwat N, Isidoro C. Resveratrol interrupts the pro-invasive communication between cancer associated fibroblasts and cholangiocarcinoma cells. *Cancer Lett.* 2018 May 23;430:160-171. doi: 10.1016/j.canlet.2018.05.031.

2. Ha JH, Radhakrishnan R, Jayaraman M, Yan M, Ward JD, Fung KM, Moxley KM, Sood AK, Isidoro C, Mukherjee P, Song YS, Dhanasekaran DN. Lysophosphatidic Acid Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response. *Cancer Res.* 2018 Jan 31. pii: canres.1624.2017. doi:10.1158/0008-5472.CAN-17-1624.

3. Thuwajit C, Ferraresi A, Titone R, Thuwajit P, Isidoro C. The metabolic cross-talk between epithelial cancer cells and stromal fibroblasts in ovarian cancer progression: Autophagy plays a role. *Med Res Rev.* 2017 Sep 19. doi:10.1002/med.21473.

Biographical sketch CIRO ISIDORO

4. Ferraresi A, Titone R, Follo C, Castiglioni A, Chiorino G, Dhanasekaran DN, Isidoro C. The protein restriction mimetic Resveratrol is an autophagy inducer stronger than amino acid starvation in ovarian cancer cells. *Mol Carcinog.* 2017 Dec;56(12):2681-2691. doi: 10.1002/mc.22711.
5. Phadngam S, Castiglioni A, Ferraresi A, Morani F, Follo C, Isidoro C. PTEN dephosphorylates AKT to prevent the expression of GLUT1 on plasmamembrane and to limit glucose consumption in cancer cells. *Oncotarget.* 2016 Dec20;7(51):84999-85020. doi: 10.18632/oncotarget.13113.
6. Ferraresi A, Phadngam S, Morani F, Galetto A, Alabiso O, Chiorino G, Isidoro C. Resveratrol inhibits IL-6-induced ovarian cancer cell migration through epigenetic up-regulation of autophagy. *Mol Carcinog.* 2017 Mar;56(3):1164-1181. doi: 10.1002/mc.22582.
7. Klionsky DJ, et al., Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy.* 2016 Jan 2;12(1):1-222.
8. Tang H, Sebti S, Titone R, Zhou Y, Isidoro C, Ross TS, Hibshoosh H, Xiao G, Packer M, Xie Y, Levine B. Decreased BECN1 mRNA Expression in Human Breast Cancer is Associated with Estrogen Receptor-Negative Subtypes and Poor Prognosis. *EBioMedicine.* 2015 Mar;2(3):255-263.